Clinical trials: RA - Rheumatoid Arthritis
Rheumatoid Arthritis
Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
The purpose of this study is to evaluate the safety and efficacy of golimumab in Chinese patients with rheumatoid arthritis.
- Trial name
- NCT01248780
- Testing
- Golimumab, Methotrexate (MTX)
- Where
- 9 sites in China
- Volunteers
- 264 people
- Sponsor
- Centocor, Inc.
Arthritis, Rheumatoid
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
- Trial name
- NCT03241446
- Testing
- Tilmanocept
- Sponsor
- Navidea Biopharmaceuticals
Arthritis, Rheumatoid
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Part 1 of this trial will assess the safety and effectiveness of subcutaneous (SC) golimumab administered by autoinjector once monthly, when combined with different disease-modifying antirheumatic drug (DMARD) regimens used in…
- Trial name
- GO-MORE (NCT00975130)
- Testing
- SC golimumab, IV golimumab
- Volunteers
- 3,366 people
- Sponsor
- Merck Sharp & Dohme LLC
Rheumatoid Arthritis
Changes of Depression After First-year of Tofacitinib in RA Patients
12-month, single arm, prospective, non-interventional, multi-center study according to Czech legal definitions (Law 378/2007 Sb.).The primary objective of this study is to describe and evaluate the changes of depression level…
- Trial name
- NCT03992781
- Where
- 6 sites in Czechia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Arthritis, Rheumatoid, Healthy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy
To evaluate the safety and tolerability of multiple doses of BI 655064 administered subcutaneously in healthy volunteers (HVs) and in rheumatoid arthritis (RA) patients.
- Trial name
- NCT01751776
- Testing
- BI 655064
- Where
- 25 sites in Czechia, Germany and 4 more
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Gastric Ulcer, Duodenal Ulcer
Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID
The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily…
- Conditions
- Gastric Ulcer, Duodenal Ulcer, Rheumatoid Arthritis, Osteoarthritis
- Trial name
- NCT00542789
- Testing
- Esomeprazole
- Where
- 39 sites in Japan
- Volunteers
- 343 people
- Sponsor
- AstraZeneca
Rheumatoid Arthritis
Study Evaluating the Efficacy and Safety of Etanercept
To assess the efficacy of etanercept 25 mg administered subcutaneously twice-weekly for 12 weeks in patients with active RA for whom classical antirheumatic therapy is insufficient or inappropriate.
- Trial name
- NCT00546533
- Testing
- Etanercept
- Volunteers
- 40 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Rheumatoid Arthritis
To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
To demonstrate that CT-P13 is equivalent to China-approved Remicade at Week 14, in terms of efficacy as determined by clinical response according to the change from baseline in disease activity.
- Trial name
- NCT03707535
- Testing
- CT-P13, Remicade
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis
This is a randomized double-blind comparative parallel group study of the efficacy and safety of tocilizumab biosimilar Complarate® and Actemra® in the treatment of patients with rheumatoid arthritis with moderate to high disease…
- Trial name
- NCT06475508
- Testing
- Complarate®, Actemra®
- Where
- 28 sites in Russia
- Volunteers
- 465 people
- Sponsor
- AO GENERIUM
Arthritis, Rheumatoid
Subject Insights to Understand Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease affecting the joints and can lead to joint pain, swelling, redness and stiffness and can cause deformity, loss of strength and immobility.
- Trial name
- NCT03285191
- Testing
- Numerical rating scale, Real-time data capture app
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- GlaxoSmithKline
Osteoarthritis, Rheumatoid Arthritis
Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug Treatment
The purpose of this study is to evaluate the safety of long-term treatment with HZT-501, a fixed-dose combination oral tablet of 800 mg ibuprofen and 26.6 mg famotidine for patients that require long-term NSAID treatment.
- Conditions
- Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome
- Trial name
- NCT00984815
- Testing
- HZT-501
- Where
- 4 sites in United States
- Volunteers
- 86 people
- Sponsor
- Amgen
Arthritis, Osteoarthritis
A Study of the Effect on Pain Control of Treatment With Fentanyl, Administered Through the Skin, in Patients With Rheumatoid Arthritis or Osteoarthritis
The purpose of this study is to assess the degree of pain control achieved by treatment with fentanyl, administered via adhesive patches applied to the skin ('transdermal system") in patients with rheumatoid arthritis or…
- Conditions
- Arthritis, Osteoarthritis, Rheumatoid Arthritis
- Trial name
- NCT00524160
- Testing
- Fentanyl transdermal patch
- Volunteers
- 264 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Rheumatoid Arthritis
A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)
This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX.
- Trial name
- MUSICA (NCT01185288)
- Testing
- Adalimumab, Methotrexate
- Where
- 49 sites in United States, Puerto Rico
- Volunteers
- 309 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited
Rheumatoid Arthritis
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis
This open-label single-arm study will evaluate the safety, tolerability and efficacy of tocilizumab [RoActemra/Actemra] in patients with moderate to severe rheumatoid arthritis who experience an inadequate clinical response to a…
- Trial name
- NCT01089023
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 9 sites in Bahrain, Iran and 3 more
- Volunteers
- 95 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis, Arthritis of Ankle
Vantage Mobile Bearing Total Ankle System Post Market Clinical Follow-up (Outside US)
The objectives of this study are to evaluate the performance and safety of the Vantage Mobile-Bearing Total Angle System. This study will follow subjects for a period of up to 10 years post-surgery.
- Conditions
- Rheumatoid Arthritis, Arthritis of Ankle, Failure, Prosthesis
- Trial name
- NCT05691868
- Where
- 2 sites in Spain, Switzerland
- Volunteers
- 400 people
- Sponsor
- Exactech
Rheumatoid Arthritis
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX
This randomized, multicenter, double-blind, parallel group study will evaluate the impact of MTX discontinuation on the efficacy of SC TCZ in participants with moderate to severe active rheumatoid arthritis who have an inadequate…
- Trial name
- NCT01855789
- Testing
- Tocilizumab (TCZ), Methotrexate (MTX)
- Where
- 155 sites in United States
- Volunteers
- 718 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment
The study is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of 12 weeks daily treatment with 100 mg AP1189 in RA patients who are to start up-titration with methotrexate…
- Trial name
- EXPAND (NCT05516979)
- Testing
- 100 mg AP1189
- Where
- Moldova
- Volunteers
- 127 people
- Sponsor
- SynAct Pharma Aps
Osteoarthritis, Hip, Rheumatoid Arthritis
A Clinical Investigation of the Balance® Microplasty™ Hip System
The purpose of this prospective clinical data-collection is to document the performance and clinical outcomes of the Balance® Microplasty™ Hip System.
- Conditions
- Osteoarthritis, Hip, Rheumatoid Arthritis, Avascular Necrosis
- Trial name
- NCT00699088
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- Biomet Orthopedics, LLC
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.